Free shipping over €250 · Tracked, discreet delivery in Europe

IGF-1 tripeptide analogue

Trofinetide

Daybue

Approved medicineNot yet reviewedPeptide

In short: A synthetic analogue of the N-terminal tripeptide of IGF-1. Approved by the FDA in 2023 for Rett syndrome.

Regulatory status

  1. Cosmetic ingredient
  2. Research compound
  3. In clinical trials
  4. Approved medicine

Approved as a medicine by the FDA or the EMA for at least one indication. Approval covers the named indication and formulation only.

A full research summary for this compound has not been published in the library yet. The status and class above are current.

Common questions

Is Trofinetide an approved medicine?

Approved medicine. Approved as a medicine by the FDA or the EMA for at least one indication. Approval covers the named indication and formulation only.

How much human research is there on Trofinetide?

A full research summary for this compound has not been published in the library yet. The status and class above are current.

Does UU supply Trofinetide?

No. It appears in the library for reference only, so the field can be read in one place.

More in Brain, mood & sleep

Back to the library
  • Researchuu

    Selank

    Tuftsin analogue

    Early human data
  • Researchuu

    Semax

    ACTH(4-10) analogue

    Mixed evidence
  • Researchuu

    DSIP

    Neuropeptide

    Mixed evidence
  • Researchuu

    Pinealon

    Short bioregulator peptide

    Preclinical
  • Researchuu

    Dihexa

    Angiotensin IV analogue

    Preclinical
  • Researchuu

    ARA-290

    Erythropoietin-derived peptide

    Early human data

The UU library is an educational reference. It is not medical advice, does not make a health claim, and does not tell anyone how to use a compound. UU products are sold for laboratory research use only and are not for human consumption. Regulatory status changes: confirm it with the relevant authority before relying on it.